|Bid||0.000 x 800|
|Ask||0.000 x 1800|
|Day's Range||0.705 - 0.748|
|52 Week Range||0.332 - 0.865|
|Beta (3Y Monthly)||3.10|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.29|
NEW YORK, Oct. 19, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
NEW YORK, Oct. 1, 2018 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or "the Company"), announced today that is has launched its Iomab-ACT program offering its next-generation, chemo-free, targeted lymphodepletion technology to the CAR-T industry. The Iomab-ACT program technology has the potential to be a major improvement over current lymphodepletion regimens due to its targeted mechanism of action that may improve CAR-T cell expansion, reduce CAR-T related toxicities and expand patient access to CAR-T treatment. Actinium recently announced that it has developed an initial estate of six patents related to the Iomab-ACT program supported by its internal research and that it has the support of key physicians from the Froedtert and the Medical College of Wisconsin for the clinical use of Iomab-ACT in conjunction with CAR-T therapy.
- Conference call and webcast today at 4:15 PM ET - Dr. Nirav Shah, Assistant Professor of Medicine, Division of Hematology and Oncology at Froedtert and the Medical College of Wisconsin will discuss Actinium's ...
NEW YORK , Sept. 20, 2018 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) today announced that the Company will participate in the Oppenheimer & Co. Fall Summit Focused on Specialty ...
A look at the shareholders of Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) can tell us which group is most powerful. Generally speaking, as a company grows, institutions will increase their ownership. Conversely,Read More...
NEW YORK, Sept. 18, 2018 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or "the Company"), announced today that it will unveil a new clinical initiative that expands the Company's pipeline into the CAR-T space. CAR-T is a type of cellular therapy that genetically alters a patient's own T cells to target and kill their cancer cells.
NEW YORK, Sept. 6, 2018 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) today announced the appointment of Robert N. Daly, M.S., Ph.D., to the position of Vice President, Head of Clinical Operations, effective immediately. In this role, Dr. Daly will oversee all clinical operations, with a focus on executing Actinium's progressing pivotal Phase 3 trial for Iomab-B as a targeted conditioning agent, driving forward the Company's growing CD33 program including its advancement in targeted conditioning, as well as future clinical trial expansion for the entire pipeline.
- Chief Medical Officer, Dr. Mark Berger, to participate in a panel at the B. Riley FBR Healthcare Conference on September 4, 2018 NEW YORK , Sept. 4, 2018 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. ...
- Conference call to be held at 9:00 AM ET on Wednesday, August 15, 2018 NEW YORK , Aug. 14, 2018 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or "the ...
On Friday, June 29, 2018, US markets saw broad based gains with six out of nine sectors finishing the trading sessions in green. All you have to do is sign up today for this free limited time offer by clicking the link below.
On June 18, Actinium Pharmaceuticals (ATNM) stock rose ~25.6% to reach $0.63. The close on June 18 was ~89% higher than its 52-week low of $0.33 on April 24. In the week ended June 15, Actinium Pharmaceuticals stock closed at $0.50, which reflected ~15% growth from the prior week’s close of $0.44 on June 8.
If you are a shareholder in Actinium Pharmaceuticals Inc’s (AMEX:ATNM), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...
LONDON, UK / ACCESSWIRE / June 4, 2018 / If you want a free Stock Review on AXON sign up now at www.wallstequities.com/registration. In today's pre-market research, WallStEquities.com scans Actinium Pharmaceuticals Inc. (NYSE AMER: ATNM), Amarin Corp. PLC (NASDAQ: AMRN), Apricus Biosciences Inc. (NASDAQ: APRI), and Axovant Sciences Ltd (NASDAQ: AXON).
Stock Monitor: Auris Medical Holding Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 02, 2018 / Active-Investors.com has just released a free research report on Actinium Pharma, Inc. (NYSE: ATNM ...